Focused On-demand Library for Interleukin-12 subunit beta

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P29460

UPID:

IL12B_HUMAN

Alternative names:

Cytotoxic lymphocyte maturation factor 40 kDa subunit; IL-12 subunit p40; NK cell stimulatory factor chain 2

Alternative UPACC:

P29460

Background:

Interleukin-12 subunit beta, also known as IL-12 subunit p40, plays a pivotal role in the immune system. It acts as a growth factor for activated T and NK cells, enhances NK cell activity, and stimulates IFN-gamma production. This cytokine, in association with IL23A, forms the IL-23 interleukin, crucial for both innate and adaptive immunity. IL-23 promotes pro-inflammatory cytokine production and is vital in autoimmune inflammation and potentially in tumorigenesis.

Therapeutic significance:

Interleukin-12 subunit beta is implicated in Immunodeficiency 29 and Psoriasis 11, diseases characterized by impaired immunity and chronic inflammation, respectively. Understanding its role could lead to novel treatments for these conditions, highlighting its therapeutic significance in modulating immune responses and inflammation.